Purpose: Non-invasive imaging is central to hepatocellular carcinoma (HCC) diagnosis; however, conventional modalities are limited by smaller tumors and other chronic diseases that are often present in patients with HCC, such as cirrhosis. This pilot study evaluated the feasibility of (4S) 
Introduction
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and ranks fifth and seventh among men and women, respectively, in worldwide cancer incidence [1] . Though HCC has historically affected the continent of Asia disproportionately (~80 % of cases), the American Cancer Society estimates the diagnosis of greater than 39,000 new cases of primary liver cancer in the USA this year, with approximately 75 % of these being HCC [2] . Additionally, both the incidence of liver cancer and liver cancer-associated deaths are increasing [1, 2] .
Liver disease and cirrhosis due to hepatitis B (HBV), hepatitis C (HCV), and non-alcoholic steatohepatitis (NASH) are the greatest contributors to the development of HCC [3] . Surgery is the best treatment option for HCC, and patients are evaluated by using BMilan^criteria (single tumor, diameter ≤5 cm; ≤3 tumors, each diameter ≤3 cm) [4] . However, the clinical application of Milan criteria is limited by the sensitivities of X-ray computed tomography (CT) and magnetic resonance imaging (MRI), which are diminished by the architectural distortions within the liver that are characteristic of cirrhosis [5] . While the overall sensitivities of CT and MRI in the setting of HCC are typically reported in the 60-70 % range, smaller lesions (1-2 cm) can exhibit a much lower rate of detection (40 %) [6] [7] [8] . The specificity of CT and MRI are also limited, as several benign conditions in the liver, often associated with cirrhosis, can be challenging to distinguish from neoplasia without biopsy or extensive imaging follow-up [7] . Therefore, improved ways to image HCC could enable improved diagnosis and staging, both of which would lead to improved clinical care for these patients.
The diverse background in which HCC develops, without a predictable trajectory of mutations leading to tumorigenesis, makes molecular imaging, such as positron emission tomography (PET), an attractive approach for this disease. To date, the role of PET imaging in HCC is not well established. Collective experience with the most widely used PET tracer in oncology, 2-deoxy-2-[ 18 F ]FDG in HCC appears to be limited primarily to high-grade/poorly -differentiated lesions and demonstrates a modest overall sensitivity of lesion detection of 50 % [9, 10] . In contrast, [ 11 C]acetate, another tracer explored for HCC detection that takes advantage of the pathway that synthesizes free fatty acids, accumulates primarily in low-grade/well-differentiated HCC lesions [4, 10] . Dual-tracer [ 18 F]FDG and [ 11 C]acetate PET studies have shown encouraging results, with one study reporting overall sensitivity and specificity of greater than 90 % in orthotopic liver transplantation (OLT) patients with cirrhosis [8] . However, there are several important drawbacks of dualtracer studies that limit routine adoption, including additional procedural complexity, greater cost, and greater risk to patients and clinical personnel. Additionally, the short halflife of [ 11 C]acetate adds further technical challenges. Thus, an alternative PET tracer with a suitable half-life for distribution that exhibits a high rate of HCC detection and sensitivity for both well-differentiated and poorly -differentiated tumors would be very clinically attractive.
Pilot After acidic deprotection, neutralization, and aqueous dilution, the tracer was purified over SPE cartridges and finally formulated for i.v. injection by passing the solution through a sterile filter. The synthesis was performed within an automated synthesis module (GE MX Reaction Module) in a lead-shielded hot cell. The production methods, sterile filtration, and formulation allowed for the production of a sterile and pyrogen-free solution ready for injection. A small aliquot was removed for analysis to confirm the quality of the final product solution. The radiochemical synthesis of sodium [ 11 C]acetate began with [ 11 C]CO 2 gas, which was made by proton irradiation of a high-pressure gas target containing 99 % nitrogen and 1 % oxygen gas. The [ 11 C]CO 2 was then purified by trapping on activated molecular sieves (4 Å) followed by heating with a flow of pure nitrogen to release the [ 11 C]CO 2 gas. The [ 11 C]CO 2 -containing gas was bubbled directly into a THF-diluted solution of methylmagnesium chloride (3.0 M). Upon completion of the [ 11 C]CO 2 delivery, the remaining methylmagnesium chloride was quenched by using a dilute solution of sulfuric acid. The reaction mixture was then transferred through a SCX cartridge, a SAX cartridge, and an IC-OH cartridge. All of the purification cartridges and the reaction vessel were then washed with water. The IC-OH cartridge was then isolated, and using saline, the sodium [ 11 C]acetate was eluted from the cartridge through a 0.22-μm sterilizing filter and into the final vial. The concentration was then adjusted to not exceed 50 mCi/ml, and a small aliquot was removed for analysis to confirm the quality of the final product solution. All released doses exceeded 266 Ci/mmol with radiochemical purity greater than 90 % for [ 18 
Materials and Methods

Patient Population and Selection
PET/CT Protocol
Patients were instructed to fast (nothing by mouth except for water and some medications) for at least 6 h prior to imaging and to refrain from smoking on the day of the imaging procedure. [12] . Twenty minutes following intravenous administration of [
11 C]acetate (7.4 MBq/kg body weight), the patient was positioned on the imaging table, and a whole body (vertex of the skull to mid-thigh) transmission CT scan acquired (~90 s) followed by a whole body (vertex of the skull to mid-thigh) PET scan at 4 min/bed position (~40 min). For 
Image Analysis
The research SOC MRI and CT and research PET/CT images were independently evaluated by an experienced nuclear medicine physician. Quantitative measurements of uptake were in accordance with PETCIST criteria as described by Wahl et al. [13] , with anatomic measurements as described by RECIST 1.1 [14] . Full access to prior imaging (CT, MRI, and ultrasound) was allowed. There was one observer, with 15-years experience with PET/CT and 35+ years of experience in medical imaging, with extensive experience in investigative imaging, and with American board certifications in both diagnostic radiology and nuclear medicine. The observer was not blinded to pathology results when they were available. Sixty minute [
18 F]FSPG scans were used to determine standardized uptake values (SUVs). Maximum standardized uptake values (SUV max ) were normalized to lean body mass and measured with a 1 ml spherical region of interest over the area of greatest uptake in the tumor being measured. Background uptake (SUV max ) of normal organs was obtained by using a 3 cm diameter spherical region of interest. Normal liver uptake was measured in the peripheral right lobe, with care to avoid inclusion of major vascular structures, anatomic abnormalities, or areas of tumor. These measurements were performed by using Xeleris 3.0 workstation hardware and software from GE Healthcare, Waukesha, MI, USA. Maximum intensity projection images and fusion of axial PET images with accompanying CT were performed by using OsiriX (v5.5.2, Pixmeo, Geneva, Switzerland The Cancer Genome Atlas RNA-Seq Analysis RNA expression levels of the x C− transporter (gene symbol SLC7A11) were obtained for stage 1 HCC and matched normal liver samples from The Cancer Genome Atlas (TCGA). A paired t test was performed to assess the statistical significance of the observed differential expression between HCC and normal samples. 
Tissue Microarray and Immunohistochemistry
The tissue microarray (TMA) was created by using duplicate 1 mm cores from 83 HCC tumors and matched background liver. All cases were from hepatectomies performed for liver transplantation or from partial hepatectomy specimens. Etiology of underlying liver disease was chronic hepatitis C with or without alcohol abuse (42), chronic hepatitis B with or without alcohol abuse or concomitant hepatitis C infection (9), alcohol abuse without viral infection (4), hemochromatosis (1), non-alcoholic fatty liver disease (5), and no or unknown liver disease (22) . TMAs were sectioned onto slides and immunohistochemistry (IHC) to detect the x C− transporter performed. First, antigen retrieval was carried out in pH 6.0 citrate buffer in a pressure cooker at 104°C for 20 min and then cooled for 10 min at room temperature. Samples were then quenched in 0.02 % H 2 0 2 with sodium azide for 5 min, blocked in serum-free protein block Dako X0909 for 15 min, and incubated in primary antibody (xCT antibody; Novus) at 1:2000 dilution for 60 min. Detection was carried out by incubating for 20 min in Dako Envision plus HRP-labeled polymer and then incubating with chromogen DAB for 5 min. Samples were determined to be positive or negative for x C− expression, and categorical variables (e.g., tumor grade) were summarized in frequency tables and compared among important subgroups by using the chi-squared test.
Pathology
When possible, diagnosis of HCC lesions was confirmed by CTguided needle biopsy. The explanted liver sections shown in Fig. 4d for patient 5 were obtained following a right lobe, partial hepatectomy. The liver was serially sectioned in slices measuring 5 mm or less. Gross examination of liver explant specimens was performed by an expert GI pathologist for final determination of HCC status of suspected lesions.
Results
x C− transporter Expression Is Elevated in HCC Tumor Tissue
The PET tracer [ 18 F]FSPG takes advantage of increased x C− transporter activity, which is associated to part of the truncated tricarboxylic acid (TCA) cycle often utilized as an alternative metabolic pathway in tumor cells (Fig. 1) . To determine whether HCC tumors have elevated RNA levels of the x C− transporter (gene symbol SLC7A11), we queried RNA-Seq data from TCGA to compare HCC and normal liver tissue. Supporting our hypothesis that [
18 F]FSPG PET/ CT may be useful in the detection of low-grade HCC, we observed that over 80 % of stage 1 HCCs exhibited SLC7A11 expression that exceeded background liver in matched specimens (Fig. 2, n = 16 , p G 0.01), with over half of the specimens exhibiting an expression difference that exceeded 2-fold. We also evaluated x C− protein levels by IHC in normal liver and HCC tumors by using a TMA of 83 patient specimens (Fig. 3) . Similar to the RNA-Seq data, approximately 70 % of the HCCs evaluated were positive for x C− transporter expression by IHC analysis. Immunoreactivity of background, non-tumor liver was negligible, yet tumors exhibited robust staining that was confined to the tumor cells and was primarily localized to the cell membrane. While a greater proportion of higher grade (3 and 4) HCCs were positive for SLC7A11, we were encouraged that approximately half of the low-grade tumors exhibited robust staining. These data showing elevated x C− in HCC tumors suggest that [ 18 18 F]FSPG PET/CT in this setting. SUV values ranged from 0.7 to 9.2 for HCC tumors, while SUV values for background liver were much lower, ranging from 0.5 to 1.9. It was not obvious that the presence or absence of cirrhosis affected the background liver SUV, as patient 6 (cirrhosis) and patients 5 and 7 (no cirrhosis) exhibited the lowest background liver uptake, while patient 3 (no cirrhosis) exhibited one of the highest SUV background values. Regardless, the low background uptake appeared to be a major contributor to the promising tumor-to-liver background ratios achieved in detected HCC tumors. Among patients whose HCC tumor differentiation status was known ( 18 F]FSPG was observed in this patient, with retained activity observed in the oral cavity, pancreas, fundus of the stomach, and kidneys, with evidence of urinary excretion (Fig. 4a) . Background liver accumulation was modest in this patient (SUV 0.5). Two lesions were easily detected by [ 18 F]FSPG PET/CT in this patient, with one being a larger HCC (4.7 cm, SUV 9.2; Fig. 4a , b, Table 1 ) that was readily identified on SOC MRI (Fig. 4c,  left image) . Importantly, however, a much smaller satellite lesion (1.2 cm, SUV 3.8; Fig. 4a , b, Table 1 ) was also easily detected by [ 18 F]FSPG PET, an HCC later confirmed at resection, that was suspicious for HCC by SOC MRI but significantly less obvious (Fig. 4c, right image) . Liver explant analysis following resection (Fig. 4d) 18 F]FSPG accumulation in cancer cells. As part of the truncated TCA cycle, L-glutamine is taken up via the ASCT2 transporter. L-glutamine is subsequently processed by GLS into L-glutamate, which is then used by the TCA cycle or transported out of the cell by the system x C-transporter in exchange for L-cystine in a rate-limiting fashion. [ 18 F]FSPG biologically functions as L-cystine and is internalized by the system x C− transporter. This provides precursors for glutathione biosynthesis and, thus, redox maintenance. GLS glutaminase, GSH1 gamma-glutamyl cysteine synthetase, GSH2 glutathione synthase, ROS reactive oxygen species. 
Discussion
With the fifth and seventh highest cancer incidences in men and women, respectively, HCC is a major health concern both in the US and worldwide. Currently, CT and MRI imaging are used to diagnose HCC; however, these imaging techniques can be confounded in patients who have cirrhosis due to structural distortions caused by the disease. As cirrhosis is a common risk factor leading to the development of HCC, alternative imaging methods such as PET could be particularly useful for HCC diagnosis. Additionally, CT and MRI imaging detection rates are much lower (40 %) for smaller lesions, which PET imaging might improve. PET is an especially useful imaging technique, as tracers are designed specifically to target molecular pathways. The [ 18 F]FSPG PET tracer employed in this study targets a pathway used by many tumor types (Fig. 1) . As a result of the truncated TCA cycle, glutamine and glutamate are often major metabolic and anabolic substrates of tumor cells, in parallel or even in lieu of glucose-derived metabolites like pyruvate. As part of this alternate pathway, L-glutamine is taken up via the ASCT2 transporter and processed into Lglutamate, which is then utilized by the truncated TCA cycle. The system x C− transporter, a glutamate-cystine exchanger [15] , also transports L-glutamate out of the cell and L-cystine into the cell in a rate-limiting fashion, thus providing precursors for glutathione (GSH) biosynthesis. [ 18 F]FSPG, which functions as a cystine mimetic, is specifically taken up via the system x C− transporter. Our RNA-Seq and IHC analyses indicated that HCC tumor tissues have elevated expression levels of the x C− transporter in comparison to non-cancerous background liver (Figs. 2  and 3 ). These data suggest that HCC cells may rely on alternative metabolism provided by the truncated TCA cycle, in the respect that [ 18 F]FSPG reflects glutamine metabolism as related to intracellular glutamate pools replenished from transported glutamine.
A number of groups have examined the metabolic characteristics of HCC and found elevated serum levels of glutamate and reduced glutamine levels in patients with HCC [16] [17] [18] [19] [20] . This finding is consistent with the truncated TCA cycle, as the tumor cells salvage extracellular glutamine to produce glutamate, which can then be shuttled into the TCA cycle or exported from the cell via the x C− transporter to exchange for L-cystine, a substrate required for glutathione biosynthesis and cellular redox maintenance. Importantly, glutamate and glutathione metabolism have been shown to be closely correlated with the development and carcinogenesis of HCC. A study comparing the metabolic profile of non-cancerous liver and HCC tumors showed increased levels of tumor cell glutamine and glutathione in HCC tumors [21] . Thus, glutamine and glutamate may play a major role in the development, progression, and maintenance of HCC. Additionally, cystine, which is imported into the cell by the x C− transporter, is utilized as a precursor for glutathione synthesis. Redox maintenance is enabled through a constant supply of glutathione and is critical for tumor cells to protect against the toxic accumulation of reactive oxygen species. A constant supply of glutathione may enhance tumor survival, particularly during therapeutic interventions [22] , and therefore may contribute to HCC development and progression. A non-invasive imaging method that provides a surrogate biological metric for assessing glutamate/glutamine metabolism of HCC tumors has the potential to enhance HCC diagnosis. Additionally, characterization of glutamate and glutamine metabolism in HCC tumors may be useful for determining the most effective treatments for lesion response.
A previous study evaluated [ 18 F ]FSPG PET in patients with breast (n = 5) and lung (n = 10) cancer, where the tracer exhibited a promising detection rate of tumors with x C− transporter activity [22] . Baek et al. reported that elevated glycolytic activity and uptake of [ 18 F]FSPG appeared to be correlated in lung cancer, but a similar relationship was not observed in breast cancer [22] . IHC analyses of imagingmatched human pathology samples from this study showed significant correlation between [
18 F]FSPG uptake and protein expression of both the SLC7A11 subunit of the x C− heterodimer and CD44. In breast tumor samples specifically, IHC showed that the absence of CD44 correlated with low signal from [ 18 F]FSPG-PET, even if the SLC7A11 subunit was present, suggesting the importance of CD44 coexpression for system x C− function in breast cancer [22] . This relationship has not been established in other solid tumors. Future studies examining specific levels of x C− transporter and CD44 expression levels in HCC tumors in correlation with [ 18 F]FSPG uptake will be important for a more complete understanding of HCC tumors and improved detection and treatment methods.
Here high-grade/poorly -differentiated tumors [10] . Biologically, this implies that as HCC becomes more malignant and dedifferentiated, the biochemical substrates for growth shift. Importantly, the majority of smaller HCCs tend to be welldifferentiated, suggesting that [
11 C]acetate PET may play a greater role in evaluating patients with early stage disease [3] . Unfortunately, dual-tracer detection is not ideal due to cost and procedural complexity, in addition to the difficulties associated with the short half-life of 
